Neuren Pharmaceuticals dividend and valuation
Valuation
Neuren Pharmaceuticals paid $0.15 per share in dividends over the last 12 months (yield 0.7%). Last ex-dividend date: September 15, 2026. The P/E ratio is 144.0. The average price target of 6 analysts is $27.03.
Data as of November 21, 2026
Neuren Pharmaceuticals compared with similar companies
Neuren Pharmaceuticals's P/E (trailing 12 months): 144.0, +111% against the median of a group of 6 similar companies (68.2).
| Metric | Neuren Pharmaceuticals | Median | 25th–75th percentile | Band |
|---|---|---|---|---|
| P/E (trailing 12 months) | 144.0 | 68.2 | 40.5 – 95.9 | High |
| Forward P/E | 36.1 | 36.1 | 26.0 – 45.4 | Middle |
| EV/EBITDA | 180.3 | 67.6 | 30.4 – 135.7 | High |
| Price/book | 8.21 | 4.64 | 2.59 – 7.27 | High |
| Price/sales | 39.4 | 18.4 | 7.40 – 43.6 | Middle |
| Gross margin | 29.6% | 77.3% | 49.8% – 84.4% | Low |
| Operating margin | 19.9% | 14.0% | -18.8% – 20.5% | Middle |
| Net margin | 29.1% | 3.8% | -61.6% – 25.3% | High |
| ROE | 6.2% | 10.4% | -1.8% – 35.7% | Middle |
Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.
TickerLandia analysisHow it is calculated
Companies in the group: same industry, similar size
Neuren Pharmaceuticals: valuation over time
On the latest fiscal year's earnings (2025), Neuren Pharmaceuticals's P/E today is 90.1, above the median of its last 5 fiscal years (45.2; between 11.5 and 91.4 from 2017 to 2025). Relative to earnings, the stock costs more than it used to.
| Fiscal year | Price at year end | Earnings per share | P/E |
|---|---|---|---|
| 2025 | $18.61 | $0.23 | 80.0 |
| 2024 | $12.50 | $1.09 | 11.5 |
| 2023 | $24.97 | $1.20 | 20.8 |
| 2022 | $7.95 | $0.00 | — |
| 2021 | $3.77 | -$0.07 | — |
| 2020 | $1.28 | -$0.09 | — |
| 2019 | $2.48 | -$0.11 | — |
| 2018 | $1.40 | $0.03 | 45.2 |
| 2017 | $3.20 | $0.03 | 91.4 |
| 2016 | $1.16 | -$0.14 | — |
TickerLandia calculation: closing price on the last trading day of the fiscal year divided by diluted earnings per share from the annual report (positive earnings only). Prices adjusted for splits. Today's P/E is today's price divided by the latest fiscal year's earnings per share, so it compares with the years above.
TickerLandia analysisHow it is calculated
Other metrics
Valuation multiples
- Market cap
- $2.74B
- Enterprise value
- $2.5B
- EV/revenue
- 36.0
Profitability and growth
- ROA
- 2.6%
- ROIC
- 2.6%
- Revenue growth (year over year)
- 17.3%
- Earnings growth (year over year)
- -67.3%
Financial health
- Total cash
- $286.54M
- Total debt
- $0
- Current ratio
- 46.5
- Quick ratio
- 44.6
- Altman Z-Score
- 172.7
- Piotroski F-Score
- 4.00
Dividends
- Annual dividend per share
- $0.15
- Dividend yield
- 0.7%
- Payout ratio
- 100.0%
- Ex-dividend date
- September 15, 2026
Analysts and estimates
- Average price target
- $27.03
- Median price target
- $26.40
- High price target
- $29.70
- Low price target
- $25.90
- Analysts with a price target
- 6
- Consensus
- Strong buy
- Forward EPS
- $0.60
- EPS estimate, current year
- $0.43
Shares and trading
- Beta
- 1.59
- Average volume
- 436.2K
- Shares outstanding
- 126.77M
- Float
- 109.86M
- Institutional ownership
- 23.1%
- Insider ownership
- 13.3%
